www.privateairny.com Private Air | Winter 2019/2020
45
FINANCE
A
silver-bullet cancer cure is still
elusive. But lab-coated armies
of researchers are making
incredible progress on the next
best thing: gene therapies that kill tumors.
Small biotech startups and pharmaceuticals
giants alike are running thousands of
clinical trials of genetic therapies the Food
and Drug Administration (FDA) had
greenlit. Unlike standard chemo, radiation,
and surgery, they enlist the body's natural
defenses to fight cancer.
For investors, the companies leading this
game-changing health trend offer great
opportunities to boost your private wealth
and public health.
e genetics revolution is part of a new wave
in healthcare called "precision medicine."
e idea is to customize treatments based
on a patient's genetics, as opposed to
standard one-size-fits-all therapies.
One way to get in on the action: Add a
biotech exchange-traded fund (ETF) to
your portfolio.
e Ark Genomic Revolution Multi
-Sector ETF (NYSE: ARKG) is a great bet.
e fund holds many gene-based biotech
stocks poised for breakout gains. ARKG's
managers project that by 2022, it'll cost less
than $100 for people to have their entire
genome mapped. By that time 170 million
people will have done it.
A second play: the SPDR S&P Biotech
ETF (NYSE: XBI), which includes
a number of small startups and larger
companies that could score big as a result of
a positive new clinical trail result or FDA
approval of a new drug or treatment.
It's a bit of a cliché, but it is true that health
and wealth are closely linked – you really
can't enjoy one without the other. And the
biotech revolution will give you the chance
to do well financially by also doing good
from a health perspective.
